Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renal pelvis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    241 result(s) found for: Renal pelvis. Displaying page 1 of 13.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-000669-39 Sponsor Protocol Number: URU04 Start Date*: 2014-06-13
    Sponsor Name:Gregers Gautier Hermann
    Full Title: Endoscopic treatment of neoplasia in the upper urinary tract and the value of fluorescence guided endoscopic follow up.
    Medical condition: Urothelial tumors in the renal pelvis
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10038517 Renal pelvis cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004857-33 Sponsor Protocol Number: 0416-ASG Start Date*: 2017-06-01
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma
    Medical condition: subjects in untreated (1st line)* and platinum-based pretreated (2nd and 3rd line) subjects with metastatic or surgically unresectable TCC *First-line has been finally stopped since 06.01.2020
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038514 Renal pelvis and ureteric cancer transitional cell metastatic LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071664 Bladder transitional cell carcinoma metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038509 Renal pelvis and ureteric cancer metastatic transitional cell LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044423 Transitional cell carcinoma ureter metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044406 Transitional cell cancer of renal pelvis and ureter metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026427 Malignant neoplasm of renal pelvis and ureter localized transitional cell LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066752 Bladder transitional cell carcinoma stage IV PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026428 Malignant neoplasm of renal pelvis and ureter metastatic transitional cell LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026426 Malignant neoplasm of renal pelvis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044428 Transitional cell carcinoma urethra metastatic LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044419 Transitional cell carcinoma of the bladder stage IV LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071080 Transitional cell carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005403-17 Sponsor Protocol Number: KH-MS-JAW-01 Start Date*: 2007-12-10
    Sponsor Name:GE Healthcare
    Full Title: A prospective, comparative single center study of Hexvix® fluorescence uretero-renoscopy and white light uretero-renoscopy in the detection of upper urinary tract urothelial cell carcinoma
    Medical condition: Upper urinary tract (ureters and pyela/renal pelvises) urothelial cell carcinoma for which blue light uretero-renoscopy and biopsies are performed for diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10026431 Malignant neoplasm of renal pelvis and ureter transitional cell regional LLT
    9.1 10038497 Renal pelvis and ureter transitional cell cancer localized LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002577-33 Sponsor Protocol Number: ICR-CTSU/2011/10031 Start Date*: 2012-01-04
    Sponsor Name:Institute of Cancer Research
    Full Title: A Phase III randomised trial of Peri-Operative chemotherapy versus sUrveillance in upper Tract urothelial cancer
    Medical condition: Upper urinary tract transitional cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044407 Transitional cell cancer of the renal pelvis and ureter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-003498-27 Sponsor Protocol Number: JEVTCC-SOGUG-2011-04 Start Date*: 2011-12-19
    Sponsor Name:Grupo Español de Tratamiento de Tumores Genitourinarios (SOGUG)-Spanish Genitourinary Oncologic Group
    Full Title: A phase II open label study of cabazitaxel in patients with advanced or metastatic transitional cell carcinoma of the urothelium who have progressed ?12 months after a previous platinum based chemo...
    Medical condition: advanced or metastatic transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001841-34 Sponsor Protocol Number: PLUTO2011 Start Date*: 2012-01-12
    Sponsor Name:NHS Greater Glasgow Health Board [...]
    1. NHS Greater Glasgow Health Board
    2. University of Glasgow
    Full Title: A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium.
    Medical condition: Relapsed or progressive Transitional Cell Carcinoma (TCC) of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044426 Transitional cell carcinoma urethra LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044420 Transitional cell carcinoma of the bladder stage unspecified LLT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044407 Transitional cell cancer of the renal pelvis and ureter PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005983-12 Sponsor Protocol Number: INT01/12 Start Date*: 2012-03-21
    Sponsor Name:ISTITUTO NAZIONALE PER LA CURA TUMORI
    Full Title: Phase II study of the fully human monoclonal antibody against transforming growth factor-beta (TGF-beta) receptor ALK1 (PF-03446962) in relapsed or refractory urothelial cancer (UC) failing first-l...
    Medical condition: Relapsed or refractory urothelial cancer after failure of 1st line platinum-containing chemotherapy regimen for metastatic disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038502 Renal pelvis and ureter neoplasms malignant HLT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044410 Transitional cell cancer of the renal pelvis and ureter recurrent PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10044412 Transitional cell carcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066750 Bladder transitional cell carcinoma recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007591-42 Sponsor Protocol Number: SPON416-07(WCTU011) Start Date*: 2009-01-14
    Sponsor Name:Cardiff University
    Full Title: A Phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advancd transitional carcinoma of the urothelium.
    Medical condition: Advanced transitional cell carcinoma of the urothelium.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005003 Bladder cancer LLT
    9.1 10038517 Renal pelvis cancer NOS LLT
    9.1 10046375 Ureter cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-004628-39 Sponsor Protocol Number: ABACUS-2 Start Date*: 2020-12-16
    Sponsor Name:Queen Mary University of London
    Full Title: A phase II study of neoadjuvant immune checkpoint inhibitors in urothelial cancer
    Medical condition: Tumours of the urothelial tract requiring surgery (T1 high grade-T4a of the bladder, rare histological subtypes) and upper urinary tract (high grade or high risk)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046384 Ureteral cancer LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026426 Malignant neoplasm of renal pelvis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-007615-82 Sponsor Protocol Number: SPON417-07 Start Date*: 2009-09-16
    Sponsor Name:Cardiff University
    Full Title: A Phase I/II single-arm trial to evaluate the combination of cisplatin and gemcitabine with the mTOR inhibitor temsirolimus for treatment of advanced cancers, including first-line treatment of pati...
    Medical condition: Advanced cancers including transitional cell carcinoma of the urothelium
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038517 Renal pelvis cancer NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046375 Ureter cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003962-24 Sponsor Protocol Number: VEN1 Start Date*: 2008-10-15
    Sponsor Name:Fredericia hospital
    Full Title: visceral pain originating from the upper urinary tract - a randomised controlled trial on the effect of morphine and oxycodone in patients undergoing percutaneus nephrolithotomy (PCNL)
    Medical condition: kidney stone
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038339 Removal of kidney stone LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-005241-36 Sponsor Protocol Number: Start Date*: 2005-06-21
    Sponsor Name:ACROSS Group
    Full Title: Phase II clinical trial of Cisplatin, Gemcitabine and Trastuzumab (Herceptin®) as first line treatment of advanced irresectable transitional-cell urothelial carcinoma with overexpression of C-erbB-2
    Medical condition: Advanced irresectable transitional-cell urothelial carcinoma, that includes cancer of the bladder, ureter and renal pelvis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004494-41 Sponsor Protocol Number: CLIN2001UCM301 Start Date*: 2021-06-11
    Sponsor Name:Steba Biotech, S.A.
    Full Title: Multicenter Phase 3 Pivotal Study to Evaluate the Safety and Efficacy of TOOKAD (padeliporfin) Vascular Targeted Photodynamic Therapy in the Treatment of Low Grade Upper Tract Urothelial Cancer
    Medical condition: Low Grade Upper Tract Urothelial Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10077840 Urothelial cancer of renal pelvis LLT
    20.0 100000004864 10046375 Ureter cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003328-35 Sponsor Protocol Number: CHD062-13 Start Date*: 2014-03-13
    Sponsor Name:Centre Hospitalier Départemental Vendée
    Full Title:
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.0 10042613 - Surgical and medical procedures 10038528 Renal stone removal PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002323-25 Sponsor Protocol Number: AA1720 Start Date*: 2017-09-22
    Sponsor Name:Center for cancer immune therapy
    Full Title: Adoptive cell therapy across cancer diagnoses
    Medical condition: Patients with metastatic solid cancers in stages III or IV regardless of diagnosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055099 Ocular cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055100 Otic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055108 Thymic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050017 Lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055104 Pharyngeal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055105 Sinus cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055096 Anal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10053548 Gastrointestinal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055097 Rectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055114 Colon cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055098 Oral cavity cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055109 Tongue cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055102 Oesophageal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050018 Renal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046394 Ureteric cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046433 Urethral cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055115 Skin cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055101 Bone cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055095 Adrenal gland cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055106 Pituitary cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055107 Thyroid cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055113 Breast cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055111 Biliary cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066879 Gallbladder cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055110 Hepatic cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055094 Cervix cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016182 Fallopian tube cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033158 Ovarian epithelial cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046887 Vaginal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10047742 Vulval cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10055103 Testicular cancer metastatic PT
    20.0 100000016906 10033605 Pancreatic cancer metastatic LLT
    20.0 100000016840 10023183 Jejunum cancer metastatic LLT
    20.0 100000016840 10013816 Duodenal cancer metastatic LLT
    20.0 100000016840 10023167 Jejunal cancer metastatic LLT
    20.0 100000017543 10038498 Renal pelvis and ureter transitional cell cancer metastatic LLT
    20.0 100000017543 10038509 Renal pelvis and ureteric cancer metastatic transitional cell LLT
    20.0 100000017725 10046377 Ureter cancer metastatic LLT
    20.0 100000017773 10046420 Urethra cancer metastatic LLT
    20.0 100000021146 10036947 Prostatic cancer metastatic LLT
    20.0 100000016931 10062478 Esophageal cancer metastatic LLT
    20.0 100000143841 10063107 Tubular breast cancer metastatic LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068694 Testicular germ cell cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068971 Germ cell cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069728 Rectosigmoid cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070902 Laryngeal cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071540 Head and neck cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10072792 Tonsil cancer metastatic PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10079104 Nasopharyngeal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-001199-23 Sponsor Protocol Number: ICR-CTSU/2014/10048 Start Date*: 2016-10-11
    Sponsor Name:The Institute of Cancer Research
    Full Title: InPACT - International Penile Advanced Cancer Trial (International Rare Cancer Initiative)
    Medical condition: Locally advanced squamous carcinoma of the penis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10034299 Penile cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-000192-17 Sponsor Protocol Number: GO-80, V1 18 Mar 05 Start Date*: 2005-05-18
    Sponsor Name:Barts & The London NHS Trust
    Full Title: Gemcitabine and Oxaliplatin in the treatment of locally advanced or metastatic transitional cell carcinoma of the urinary tract in patients with impaired renal function and patients who have progr...
    Medical condition: Locally advanced or metastatic transitional cell carcinoma of the urinary tract
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003626-40 Sponsor Protocol Number: CA209-274 Start Date*: 2016-07-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma
    Medical condition: Subjects with High Risk Invasive Urothelial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) BE (Trial now transitioned) DK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) DE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) IE (Trial now transitioned) GB (GB - no longer in EU/EEA) GR (Trial now transitioned) RO (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001930-26 Sponsor Protocol Number: LEOC/FJD-14/01 Start Date*: 2014-10-10
    Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
    Full Title: A randomized, evaluator blinded clinical trial to compare clinical efficacy of four different analgesic strategies in patients undergoing Extracorporeal Shock Wave Lithotripsy (ESWL).
    Medical condition: Pain in Nephrolithiasis in whom Extracorporeal shock wave lithotripsy is indicated
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004856 10017926 Gastrointestinal and abdominal pains (excl oral and throat) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009277-10 Sponsor Protocol Number: NCT-2008-11-02-1021 Start Date*: 2011-03-24
    Sponsor Name:University Hospital Heidelberg
    Full Title: Neoadjuvant Radiochemotherapy Combined with Panitumumab in Locally Advanced KRAS wild-type Rectal Cancer
    Medical condition: Histologically confirmed, potentially resectable rectal adenocarcinoma staged as uT3/4, N0/1 by endosonography or cT3/4 by MRI of the pelvis with or without local lymph node metastases, but without...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038052 Rectal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 09:04:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA